XML 22 R13.htm IDEA: XBRL DOCUMENT
v3.22.4

Leases | 9 Months Ended
--- | ---
Jan. 31, 2023
Leases [Abstract] |
Leases | Leases Operating Leases The Company currently leases certain office equipment and its office and laboratory facilities under non-cancelable operating leases. Rent expense for operating leases is recognized on a straight-line basis over the lease term from the lease commencement date through the scheduled expiration date. Rent expense totaled $475,000 and $469,000 for the three months ended January 31, 2023 and 2022, respectively, and $1.4 million for both the nine months ended January 31, 2023 and 2022. The Company considers its facilities adequate for its current operational needs. The Company leases the following facilities: •One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as the Company’s corporate headquarters. The lease was renewed during fiscal year 2022 and expires in November 2026. The Company recognized $20,000 and $24,000 of rent expense relative to this lease for the three months ended January 31, 2023 and 2022, respectively, and $62,000 and $70,000 for the nine months ended January 31, 2023 and 2022, respectively. •1330 Piccard Drive Suite 025, Rockville, MD 20850, which consists of laboratory and office space where the Company conducts operations related to its primary service offerings. The Company executed this lease (the "Original Premises") on January 11, 2017. The operating commencement date was August 11, 2017. This lease was originally set to expire in August 2028. ◦On March 30, 2020, the Company executed the first amendment to this lease to expand the existing premises at 1330 Piccard Drive, Suite 025 ("Expansion Premises") to add on Suites 050 and 104. This amendment also extended the current lease term by six months. The Expansion Premises operating lease commencement date was June 1, 2020 and, under the amendment, both leases expire February 28, 2029. ◦In accordance with ASC 842, "Leases", the Company evaluated the first amendment and also performed a reassessment of the existing lease for Suite 025 to determine the impact of the six-month term extension. As a result of this assessment, the Company recognized an additional operating ROU asset and related operating lease liability for Suite 025 of $118,000 and $125,000, respectively, as well as an incremental net rent expense of $8,000 during the three months ended July 31, 2020 related to fiscal year 2021. ◦Upon the Expansion Premises operating lease commencement date (June 1, 2020), the Company recognized an operating ROU asset and related operating lease liability for Suites 050 and 104 of $3.8 million, each, respectively. ◦On December 22, 2020, the Company executed the second amendment to this lease to expand the existing premises at 1330 Piccard Drive, Suites 025, 050, and 104 ("Additional Expansion Premises") and add on Suite 201. The Additional Expansion Premises operating lease commencement date is April 1, 2021 and, under the second amendment, reaffirms that all three leases expire February 28, 2029. Upon the Additional Expansion Premises operating lease commencement date (April 1, 2021), the Company also recognized an operating ROU asset and related operating lease liability for Suite 201 of $3.3 million, each, respectively. ◦For the leases related to the premises at Piccard Drive, the Company recognized $422,000 in rent expense for the three months ended January 31, 2023 and 2022, respectively, and $1.3 million in rent expense for both the nine months ended January 31, 2023 and 2022. •VIA LEONE XIII, 14, Milan, Italy, which consists of laboratory and office space where the Company conducts operations related to its flow cytometry service offerings. The Company executed the lease for its laboratory space in June 2021, and commenced occupancy during the three months ended October 31, 2021. This lease was set to expire May 2023. The Company executed a lease for its office space on October 1, 2021. This lease was set to expire September 2027. ◦Upon lease execution, the Company recognized an operating ROU asset and related operating lease liability for the lab and office space of $205,000 each, respectively. ◦On November 1, 2022, the Company executed a new lease to consolidate its office and laboratory space at a new nearby location in Italy. The new lease is set to expire October 31, 2028 and it replaces the previous two leases. ▪Upon lease execution, the Company recognized an operating ROU asset and related operating lease liability for the lab and office space of $231,000 each, respectively. ▪The original office space lease, which was set to expire September 2027, was terminated with an effective date of November 30, 2022. Upon lease termination, the Company recognized a decrease in the related net operating ROU asset and operating lease liability of approximately $40,700 and $41,500, respectively, as well as a gain on lease termination of less than $1,000. ▪The original laboratory lease, which was set to expire May 2023, was terminated in the third quarter of fiscal year 2023 with an effective date of February 2023. In accordance with ASC 842, the company performed an evaluation on the existing least to determine the impact of this termination, if any. As a result, the company recorded a reduction to both the operating ROU asset and related operating lease liability of approximately $20,000, respectively, during the three months ended January 31, 2023. ◦The Company recognized rent expense associated with these leases of $34,000 and $23,000 for the three months ended January 31, 2023 and 2022, respectively, and $81,000 and $58,000 for the nine months ended January 31, 2023 and 2022, respectively. ROU assets and lease liabilities related to our current operating leases are as follows (in thousands):
| January 31, 2023 | April 30, 2022
Operating lease right-of-use assets, net | $ | 7,590 |  | $ | 8,230 |
Current portion of operating lease liabilities | 1,166 |  | 1,054 |
Non-current portion of operating lease liabilities | 7,702 |  | 8,412 |
As of January 31, 2023, the weighted average remaining operating lease term and the weighted average discount rate were 5.96 years and 5.82%, respectively. Future minimum lease payments due each fiscal year as follows (in thousands):
Remainder of 2023 | $ | 689 |
2024 | 2,841 |
2025 | 2,889 |
2026 | 2,938 |
2027 | 2,904 |
Thereafter | 5,244 |
Total undiscounted liabilities | 17,505 |
Less: Imputed interest | (8,636) |
Present value of minimum lease payments | $ | 8,869 |
Refer to Note 5, Property and Equipment, for information on financing leases.

X
- References No definition available. + Details
Name: | us-gaap_LeasesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -URI https://asc.fasb.org/subtopic&trid=77888251 + Details
Name: | us-gaap_LesseeOperatingLeasesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration